LYKA LABS LTD.·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies

2026-08-21 NSE BSE Web 2%ESM-II Result 10 Aug

Price

73.62

+1.99%
O:73.62
H:73.62
L:73.62
C:73.62

52W Range

44.1102.99
+67%/-29%

Market Cap

₹262.75 Cr

Traded: ₹0.06 Cr (0.02%) 0.0x

Free Float: ₹98.48 Cr (0.06% of FF traded)

Volume · 60D trend

7.62 K 0.0x

Delivery: % 0.0x

View Delivery Data

Returns

1W:+0% 1M:+21% 3M:+9% 6M:+23% 12M:-5%

Valuation

P/E--
P/B2.8
P/S1.9
EV/EBIT-151.2

Business Strength

ROE9.2%
ROCE9.9%
OPM-2.3%
NPM-7.8%

Growth (3Y CAGR)

EPS-225.4%
Sales+11.0%
Profit-32.0%
3Y Return-16.0%

Balance Sheet

Debt/Equity0.5
Debt48.39 Cr
Pledge0.0%
CWIP/Fixed Asset2.3%

Cash Position

CFO/NP-50.0%
FCF-5.89 Cr
FCF 3Y Avg-23.8 Cr
Cash/MCap1.0%

Others

Div Yield0.0%
Div Payout0.0%
Cash Conv. Cycle76 days
Tradeable Free Float37.5%

MTF Exposure Trend

60 sessions · funded amount, % of FF, daily delta

Current
₹ 0
0.00% FF
60d high
₹ 2.08 L
60d low
₹ 0
60d mean
₹ 0.40 L
vs mean
▼ 100.00%

Growth Trends

Metric10Y5Y3Y1YTTMTrend
Sales
+0.0%
+8.0%
+11.0%
--
-3.0%
Stable
ROE
--
--
-2.0%
--
--
--
Return
+0.0%
-5.0%
-16.0%
-35.0%
--
Decelerating
Profit
--
+1.0%
-32.0%
--
-219.0%
Decelerating

Quarterly Results

Jun 2026

10 Aug
Rev
42 Cr
+28% YoY+51% QoQ
OPM10.8%
NPM4.8%
PAT
+123% YoY2 Cr
EPS
+119% YoY0.6

Mar 2026

25 May
Rev
28 Cr
-16% YoY-9% QoQ
OPM-23.0%
NPM-28.8%
PAT
-530% YoY-8 Cr
EPS
-526% YoY-2.1

Dec 2025

29 Jan
Rev
31 Cr
-9% YoY-16% QoQ
OPM5.4%
NPM-0.5%
PAT
-100% YoY-0 Cr
EPS
-100% YoY0.0

Sep 2025

PDF
Rev
37 Cr
-11% YoY+11% QoQ
OPM-6.9%
NPM-8.8%
PAT
-260% YoY-3 Cr
EPS
-259% YoY-0.9

Jun 2025

PDF
Rev
33 Cr
+10% YoY-1% QoQ
OPM11.1%
NPM3.0%
PAT
-35% YoY1 Cr
EPS
-35% YoY0.3

Mar 2025

PDF
Rev
33 Cr
+20% YoY-1% QoQ
OPM12.2%
NPM6.1%
PAT
+184% YoY2 Cr
EPS
+179% YoY0.5

Dec 2024

PDF
Rev
34 Cr
+4% YoY-18% QoQ
OPM15.4%
NPM8.0%
PAT
+52% YoY3 Cr
EPS
+41% YoY0.8

Sep 2024

PDF
Rev
41 Cr
+47% YoY+37% QoQ
OPM12.0%
NPM4.6%
PAT
+1500% YoY2 Cr
EPS
+493% YoY0.6

Jun 2024

PDF
Rev
30 Cr
+32% YoY+8% QoQ
OPM12.3%
NPM4.3%
PAT
+178% YoY1 Cr
EPS
+171% YoY0.4

Mar 2024

PDF
Rev
28 Cr
+25% YoY-15% QoQ
OPM7.3%
NPM-7.5%
PAT
+20% YoY-2 Cr
EPS
+36% YoY-0.6

Dec 2023

PDF
Rev
33 Cr
+83% YoY+16% QoQ
OPM21.1%
NPM5.5%
PAT
+147% YoY2 Cr
EPS
+115% YoY0.5

Sep 2023

PDF
Rev
28 Cr
--+22% QoQ
OPM14.9%
NPM-1.8%
PAT
+12% YoY-0 Cr
EPS
---0.1

Jun 2023

PDF
Rev
23 Cr
--+3% QoQ
OPM11.5%
NPM-8.1%
PAT
-574% YoY-2 Cr
EPS
---0.6

Mar 2023

Rev
22 Cr
--+25% QoQ
OPM14.8%
NPM-13.5%
PAT
+89% YoY-3 Cr
EPS
---1.0

Dec 2022

Rev
18 Cr
----
OPM12.4%
NPM-58.5%
PAT
-162% YoY-10 Cr
EPS
---3.6

Revenue & Margin Trends

Annual

Quarterly

Balance Sheet Health

Leverage

Debt / Equity0.53
Interest Coverage3.8x
Promoter Pledge0.0%
Borrowings49 Cr

Efficiency

Receivable Days100 days
Inventory Days99 days
Payable Days122 days
Cash Conversion cycle76 days

Cash Position

Operating Cash Flow5 Cr
Investing Cash Flow-9 Cr
Financing Cash Flow4 Cr
Free Cash Flow-6 Cr

Detailed Financials

Jun 2026PDF ↗
Mar 2026PDF ↗
Dec 2025PDF ↗
Sep 2025PDF ↗
Jun 2025PDF ↗
Mar 2025PDF ↗
Dec 2024PDF ↗
Sep 2024PDF ↗
Jun 2024PDF ↗
Mar 2024PDF ↗
Dec 2023PDF ↗
Sep 2023PDF ↗
Jun 2023PDF ↗
Mar 2023
Dec 2022
Sales422831373333344130283328232218
Expenses383429392929293626262624201916
Operating Profit5-62-344554274332
OPM %10.8%-23.0%5.4%-6.9%11.1%12.2%15.4%12.0%12.3%7.3%21.1%14.9%11.5%14.8%12.4%
Other Income01111110101-000-6
Interest111110111111133
Depreciation222221222334333
Profit Before Tax2-9-0-413432-23-1-2-3-10
Tax %-5.1%-6.1%-6.3%-26.6%26.7%32.9%24.3%28.4%30.6%28.2%38.6%-22.8%7.2%0.0%2.2%
Net Profit2-8-0-312321-22-0-2-3-10
Exceptional Items00000000000-00-0-7
EPS (Rs)0.6-2.10.0-0.90.30.50.80.60.4-0.60.5-0.1-0.6-1.0-3.6
Sales Growth (YoY)28.1%-16.1%-9.1%-10.9%9.7%20.4%3.8%47.0%31.6%24.9%82.7%--------
Sales Growth (QoQ)51.0%-8.8%-16.2%11.0%-1.2%-1.1%-17.9%36.7%8.4%-14.7%16.3%22.3%2.9%24.8%--
OP Growth (YoY)23.6%-258.1%-68.2%-151.3%-0.8%102.0%-24.5%18.7%40.5%-38.8%210.9%--------
OP Growth (QoQ)170.5%-490.9%165.0%-169.0%-9.8%-21.4%4.8%33.4%83.7%-70.6%64.7%58.0%-20.0%49.3%--
Profit Growth (YoY)123.0%-530.0%-100.0%-260.0%-35.0%184.0%52.0%1500.0%178.0%20.0%147.0%12.0%-574.0%89.0%-162.0%
EPS Growth (YoY)119.2%-526.0%-100.0%-259.3%-35.0%179.4%40.7%493.3%171.4%35.7%114.9%--------
EPS Growth (QoQ)126.8%--100.0%-461.5%-48.0%-34.2%28.8%47.5%163.5%-216.7%460.0%73.2%42.9%73.0%--
OP Margin10.8%-23.0%5.4%-6.9%11.1%12.2%15.4%12.0%12.3%7.3%21.1%14.9%11.5%14.8%12.4%
Net Margin4.8%-28.8%-0.5%-8.8%3.0%6.1%8.0%4.6%4.3%-7.5%5.5%-1.8%-8.1%-13.5%-58.5%
Material Cost %38.9%39.4%37.6%40.6%38.6%39.2%38.6%43.6%38.2%43.1%35.8%41.8%41.6%35.7%33.6%
Employee Cost %27.2%46.1%30.9%28.4%27.4%28.8%25.1%20.3%27.2%26.0%22.0%23.0%26.0%23.5%25.8%
P/S1.911.781.65------------------------
P/E------------------------------
P/B2.832.562.18------------------------

Shareholding Pattern

Shareholders:29.4K (+9.5%)
Current MixJun 2026

Exchange Filings

50
Company Update12 Aug 2026

As per the letter attached

Company Update11 Aug 2026

As per the letter attached

AGM/EGM11 Aug 2026

As per the letter attached

Board Meeting10 Aug 2026

As per the letter attached

Result10 Aug 2026

As per the letter attached

Company Update10 Aug 2026

As per the letter atatched

AGM/EGM10 Aug 2026

As per the letter attached

Board Meeting24 Jul 2026

Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve As per the letter attached

Company Update17 Jul 2026

As per the letter attached

AGM/EGM17 Jul 2026

As per the letter attached

Others17 Jul 2026

As per the letter attached

AGM/EGM17 Jul 2026

As per the letter attached

Company Update10 Jul 2026

As per the letter attached

Company Update08 Jul 2026

As per the letter attached

Company Update30 Jun 2026

As per the letter attached

Insider Trading / SAST30 Jun 2026

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & PACs

Insider Trading / SAST29 Jun 2026

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Gandhi & Others

Company Update26 Jun 2026

As per letter attached

Insider Trading / SAST24 Jun 2026

As per letter attached

Company Update17 Jun 2026

As per the letter attached

Company Update12 Jun 2026

As per the letter attached

Company Update11 Jun 2026

Clarification on Price Movement

Company Update11 Jun 2026

The Exchange has sought clarification from Lyka Labs Ltd on June 11, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....

BSE
Company Update27 May 2026

As per regulation 47 of the SEBI (LODR) Regulations, 2015 the extract of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31.03.2026 were published ....

Company Update26 May 2026

Annual Secretarial Compliance Report for the year ended 31.03.2026

Board Meeting25 May 2026

As per the letter attached

Result25 May 2026

As per the letter attached

Board Meeting12 May 2026

Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2026 ,inter alia, to consider and approve As per letter attached

Company Update30 Apr 2026

Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 we wish to inform you that India Rating & Research Pvt. Ltd. has assigned/affirmed the rating of the bank facilities availed ....

Others30 Apr 2026

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Company Update09 Apr 2026

As per the letter attached

Company Update09 Apr 2026

As per the letter attached

Company Update08 Apr 2026

The Exchange has sought clarification from Lyka Labs Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....

BSE
Company Update07 Apr 2026

As per the letter attached

Board Meeting31 Mar 2026

As per the letter attached

Insider Trading / SAST27 Mar 2026

Closure of Trading Window

Board Meeting23 Mar 2026

Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/03/2026 ,inter alia, to consider and approve As per the letter attached

Company Update17 Mar 2026

Update on the Scheme of Merger- Approved by NCLT Bench

Company Update06 Mar 2026

As per letter attached

Company Update20 Feb 2026

As per the letter attached

Company Update02 Feb 2026

As per the letter attached

Company Update31 Jan 2026

As per the letter attached

Board Meeting29 Jan 2026

As per letter attached

Result29 Jan 2026

As per the letter attached

Board Meeting14 Jan 2026

Lyka Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/01/2026 ,inter alia, to consider and approve As per the letter atatched

Company Update07 Jan 2026

As per letter attached

Insider Trading / SAST29 Dec 2025

As per the letter attached

Company Update22 Dec 2025

As per the letter attached

Company Update05 Dec 2025

As per letter atatched

Company Update13 Nov 2025

As per the letter attached

Annual Reports

15

2026

2025

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2010

Credit Ratings

2
fitchRating update
25 Feb 2025Report
fitchRating update
19 Dec 2023Report